2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, DOI: 10.1182/bloodadvances.2024013743.Peer-Reviewed Original ResearchPrimary treatment failureAuto-HCTStable diseaseHodgkin lymphomaPartial responseCumulative incidence of non-relapse mortalityIncidence of non-relapse mortalityAssociated with inferior PFSEfficacy of auto-HCTAssociated with inferior OSAutologous hematopoietic cell transplantationEvaluation of prognostic factorsClassical Hodgkin lymphomaNon-relapse mortalityMulticenter retrospective cohortHigh-risk diseaseHematopoietic cell transplantationLong-term efficacyPatterns of failureUS medical centersProgression of diseaseInferior PFSMedian PFSInferior OSComplete response
2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.Peer-Reviewed Original ResearchConceptsMarginal zone lymphomaRefractory marginal zone lymphomaMulticenter cohort studyPrimary refractory diseaseOverall response rateStable diseaseCohort studyComplex cytogeneticsRefractory diseaseFirst-line therapyHigh-risk subsetType of therapyProgression of diseaseInferior OSInferior PFSMedian PFSPartial responsePredictive factorsExperimental therapiesStudy populationEligibility criteriaClinical practicePatientsResponse rateIbrutinib
2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Epperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood 2019, 134: 1554. DOI: 10.1182/blood-2019-129199.Peer-Reviewed Original ResearchPR/stable diseasePrimary treatment failureClassical Hodgkin lymphomaAnthracycline-containing chemotherapy regimensOutcomes of patientsHigh-dose chemotherapyStable diseaseOverall survivalER cohortComplete remissionSeattle GeneticsSpeakers bureauPP cohortSalvage therapyChemotherapy regimensProgressive diseasePartial responseTreatment failureHodgkin's lymphomaNew agentsAdvanced-stage classical Hodgkin lymphomaFive-year overall survivalRelapsed classical Hodgkin lymphomaAutologous hematopoietic cell transplantationRefractory classical Hodgkin lymphoma